Wintop Healthcare Fund

Description

Wintop Capital in a healthcare fund in Singapore with an objective is to achieve long-term capital appreciation through investments in healthcare sector.

Informations

• Publié par: JeraldBoone
• Publié le: 12 janvier 2017
• Nombre de lectures: 4
• Langue: English
• Poids de l'ouvrage: 2 Mo

Extrait

华鑫⼤健康基⾦
WINTOP HEALTHCARE FUND DISCLAIMER
Anyinforma oncontainedwithinthispresenta onshouldnotbedeemedtocons+tuteinvestmentadvice
andshouldnotberelieduponasthebasisforadecisiontoenterintoatransac+on,orasthebasisforany
financialorinvestmentdecision.Investorsshouldalwaysseekprofessionaladviceinregardtothesuitability
ofanyinvestment.WintopCapitalPte.Ltd.acceptsnoliabilityforanylossesorconsequen+allossincurred
byinvestorsac+nguponanyinforma oncontainedwithinthispresenta on.

Thevalueofinvestmentsandtheincomearisingfromthem,candecreaseaswellasincrease,andarenot
guaranteed,whichmeansthataninvestormaynotgetbackwhattheyinvested.Changesinexchangerates
mayalsocauseaninvestmenttofluctuateinvalue.Levelsoftaxa onsdependonaninvestor'sindividual
circumstancesandthevalueofanyapplicabletaxreliefs.
WINTOP CAPITAL: A MAS-REGISTERED FUND MANAGER
WINTOPCAPITAL
WINTOPPTE.LTD.
HEALTHCARE(RegisteredFundManager)
FUND
FOUNDERS
(PrivateLimitedCompany)
HeLiMin
LeongMunWai
EXECUTIVE SUMMARY
1 2 3 4 5
Core
HighMissionInsa ableDemand BalancedStrategy SuperiorReturnCompetencies

Insa abledemandfor WintopHealthcare WHF’sinvestment Wintop’sinvestment
WHFiswellmoreandbeMer Fund(WHF)seekto strategyistohavea teampossessesthree posi+onedtodeliver
healthcareproductsand investininvestees balancedporTolioof corecompetencies– asuperiorannual
servicesinAsiawhose whocontributetothe investments–40%in domainknowledge, returnof20%p.a.
popula onisincreasingly crea onofamore technologyandR&D China/Japan
affluentandrapidlyageing efficientandeffec+ve drivencompaniesand connec+onandcapital
atthesame+me.Thereis healthcaresystem 60%inopera ng marketexperience–
alsoapoli+calandsocial withagreater healthcareen++es whichenablesittofind
urgencyinmostAsian emphasison thatarealready thoseinvesteesand
countriestoprovideat preven+onandwell- genera ngacash growthemtosuccess.
leastaminimumlevelof beingtoimprove flow.
healthcarecoverageto generalhealthand
theirci+zens. qualityoflife.
HEALTHCARE: A DYNAMIC SECTOR
WITH ATTRACTIVE GROWTH OPPORTUNITIES
$2.2trillion
InASIA
$9.3trillion
Globalhealthcarespending
(projected2018) Globalhealthcarespendingexpectedtoaccelerateataveragerateof5%
growthp.ato$9.3trillion*in2018,approx24%($2.2trillion)fromAsia
*Worldindustryoutlook:Healthcareandpharmaceu+cals,TheEconomistIntelligenceUnit,May2014
RiseofAsia AffluentLifestyle WideSpectrum Cross-BorderInterestHealthcareReform
AffluenceinAsiahasledAsiaisnowthemost Drivenneedtocontrol Healthcareoffersrangeof Asianhealthcare
tosurgeinchronicexci+ngpartofthe healthcarecostandto investmentsfromdefensive companiesaregaining
ailmentslikediabetesworldforhealthcare providebe er maturecashgenera ng confidenceandhave
andcoronarydiseasesbusinesseswithageing coverage,the assets(clinicchains& increasinglyseekto
andgrowingdemandfordemographicsand healthcaresystemis establishedpharmacies)to expandacrossthe
healthcare,includingrapidlyrisingincomes alsoundergoingradical aggressivetargetssuchas regiontobuildscale
preven+veandwell-acrosstheregion. reformswhichprovide smallcapbiotechordrug andwidenscopeof
beinghealthcare. abundantopportuni+es discoverycompaniesthat opera ons.
forinnova vefirms. poten+allyoffermul+plier
returns.
INVESTMENT STRATEGY – A BALANCED PORTFOLIO
Approximately 40% of capital to be deployed in
medical technologies, bioscience and research and
development intensive companies (“R&D Sector”)
includingthefollowingsub-sectors:
R&D
•  DrugdevelopmentSector, Medical •  Innova vemedicaldevicesandequipment
[VALUE] •  HealthcaresupplementsandnaturalremediesServices

Sector,
Approximately 60% of capital to be deployed in[VALUE]
consumer-centricmedicalservicessectors(“Medical
ServicesSector”)includingthefollowingsub-sectors:

•  Pharmaceu+calproduc+onanddistribu+on
•  Hospital&clinicsandpharmacychains
•  Healthcare services that support the healthcare
system

INVESTMENT PROCESS
RiskFocus Diversifica on
Superiorrisk-adjustedconsistentreturnsof Diversifica onofriskbynotinves+ngofmore
20%p.a.withstrongemphasisonriskrather than15%oftotalfundinanyproject.
thansimplycap+vatedbyhugepoten+al
returns.
Cross-BorderArbitrageValueInves ng
WHFfocusesoncompaniesthatpossessstrong Undertakecrossborderinvestmentstotake
managementandsoundbusinessmodeland advantageofvalua onarbitrageandto
seekstoaddvaluethroughfinancialdiscipline, encourageinvesteecompaniestocapturescale
opera onalandstrategicguidance .
andscopeeconomiesandbestprac+cesknow how.
Co-investment Por olioSynergy
Co-optcredibleco-investorsforvalida on,risk PorTolioobjec+veistobuildaporTolioof
mi+ga on&accesstoalargerresourcebaseto companiesthathavesynergyamong
supportthegrowthofinvesteecompanies. themselvesandcontributetothesuccessofthe
whole.
CORE COMPETENCIES
LeongMunWai Ma6ldaTan
Over30yearsofinvestmentbankingexperience: Over30yearsofinvestmentbankingexperience ：Capital
•  Instrumentalinthesuccessfulini alpublicofferings(IPOs)of •  Heldseniorbankingposi6onwithNMRothschild&Market over100companiesinSGX,HKSEandotherAsianbourses. Sons(Spore&Jakarta).
•  ManagingDirectorofaleadingSingaporestockbrokingExperience •  BoardandInvestmentcommi eememberof
company. Aventures1Fundfocusingprimarilyonhealthcare
•  Fundmanagementexperiencewithasovereignwealthfund. industry.
HeLiMin SimonSun
PresidentofZhejiangZonebannerJiuzhouGroup,aconglomerate Over40yearsofexperienceinthepetrochemical,
inChinawithbusinessesinpharmaceu cals,tradi onalChinese chemicalandpharmaceu calindustry.HeldseniorChina
medicines,chemicals,logis csandproperty. Zonebanneris execu veposi onsinglobalchemicalcompaniesinthe
Connec on controllingshareholderofaShanghai-listedpharmaceu cal US,EuropeandJapan.
company.Heisinstrumentalinpullinginapanelofmedical
expertstoprovidespecialistadvicetotheFund.

DrHwangChiLooi DrGuZiQiang
Over40yearsofR&D,managementandconsul6ngexperiencein Over25yearsworkingexperiencesinpharmaceu6cal
globalpharmaceu calcompaniesandtheirChinesejoint industry,including15yearswithUSFDAregula6ons,Domain
ventures.SeniorRegulatoryScien6stoftheSingapore’sHealth guidance,proceduresintheareaofChemistry,
Knowledge ScienceAuthority. ManufacturingandControls(CMC)andCurrentGood
ManufacturingPrac6ce(CGMP).


INVESTMENT STRATEGY + CORE COMPETENCIES ＝
SUPERIOR RETURNS
CapitalMarkets
Experience
Beber Stronger
Investee Bargaining
Quality Power
SUPERIOR
RETURNS
Domain ChinaBigger
ExpertKnowledge Connec on NetworkCONFIRMED DEAL PIPELINE
Drugfor
Periodon s
•  TheinvesteeisaUKbasedandthemanagement
team comprised of ex-senior execu+ves from
Novar+sPharmaceu+cals.
•  Reposi+oningofanexis+ngdrugcompoundfor
treatment of a prevalent dental disease and
preventtoothloss.
•  Es+mated market size to be about USD2bn
currently but growing because of ageing
popula on and greater awareness of good
dentalhealth.
•  Exit through sale to large pharma a er
comple+onofphase2trialsintwoyears.
•  Expectedannualreturnisover30%p.a.